06:00 AM EDT, 07/01/2025 (MT Newswires) -- Alvotech ( ALVO ) said Tuesday it has partnered with Advanz Pharma for the supply and commercialization of AVT10, its biosimilar candidate to Cimzia, in Europe.

Cimzia, owned by biopharma firm UCB, is indicated for a variety of inflammatory diseases, including for the treatment of chronic rheumatic diseases, especially for women of childbearing age.

Alvotech ( ALVO ) and Advanz have previously entered into partnership agreements for biosimilar candidates to more than 10 reference biologics.

The companies expect to launch their first biosimilars in Europe in Q4 2025.